Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

P-glycoprotein (Pgp) plays a significant role in the disposition of cardiac glycoside (CG) drugs across the cell membrane. The relatively narrow therapeutic indices of these drugs, coupled with the co-administration of drugs that inhibit Pgp's transport mechanism, often cause an increased level of CG in the patient's plasma, resulting in fatal arrhythmia. Therefore, understanding the underlying mechanism of the CG-Pgp interaction is necessary to circumvent Pgp-mediated transport and effectively design next-generation CGs. In this study, we conducted a comparative analysis to examine the interaction with Pgp and further understand the Pgp-mediated transport of digoxin, digitoxin, digoxigenin, and digitoxigenin. Through the drug-induced kinetic studies of Pgp, our findings suggest that each of the four drugs tested has a single binding site within Pgp. The CG-Pgp binding studies demonstrated that digoxin, digitoxin, and digoxigenin had relatively higher binding affinities. The CG-mediated conformational changes in Pgp indicated that each of the drugs shifts Pgp to an "outward-open" conformation in a nucleotide-dependent manner. STDD NMR indicated that the protons within the δ-lactone ring and the tri-D-digitoxose sugar moieties (glycones) predominantly interact with Pgp. Finally, a model was proposed for CG-induced Pgp-mediated ATP hydrolysis and transport by integrating our data with previously published Pgp-mediated CG transport results.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12386283PMC
http://dx.doi.org/10.3390/ijms26167813DOI Listing

Publication Analysis

Top Keywords

pgp-mediated transport
12
digoxin digitoxin
8
digitoxin digoxigenin
8
pgp
7
transport
6
drugs
5
elucidating complex
4
complex structural
4
structural molecular
4
molecular mechanisms
4

Similar Publications

P-glycoprotein (Pgp) plays a significant role in the disposition of cardiac glycoside (CG) drugs across the cell membrane. The relatively narrow therapeutic indices of these drugs, coupled with the co-administration of drugs that inhibit Pgp's transport mechanism, often cause an increased level of CG in the patient's plasma, resulting in fatal arrhythmia. Therefore, understanding the underlying mechanism of the CG-Pgp interaction is necessary to circumvent Pgp-mediated transport and effectively design next-generation CGs.

View Article and Find Full Text PDF

Ruxolitinib, a clinically approved JAK1/2 inhibitor used in the treatment of hematologic malignancies and inflammatory conditions, has been shown to interfere with the function of cytotoxic T lymphocytes (CTLs). Previous studies supported the involvement of the multidrug resistance transporter P-glycoprotein (Pgp/ABCB1) in CTL biology; however, the nature of its regulation remains unclear. To address this, we investigated the impact of ruxolitinib on Pgp expression and function in human CD8 T cells.

View Article and Find Full Text PDF

A series of marchantin C-NO donor hybrids were designed, synthesized, and evaluated for their antitumor activity and . Notably, MC-furoxan hybrid exhibited the best selective inhibitory activity against MCF-7/ADR (IC = 0.024 μM) with 883 times potency compared with MCF-7 cells (IC = 21.

View Article and Find Full Text PDF

Innovative -acridine thiosemicarbazones (NATs) were designed along with their iron(iii), copper(ii), and zinc(ii) complexes. Lysosomal targeting was promoted by specifically incorporating the lysosomotropic Pgp substrate, acridine, into the thiosemicarbazone scaffold to maintain the tridentate N, N, S-donor system. The acridine moiety enables a significant advance in thiosemicarbazone design, since: (1) it enables tracking of the drugs by confocal microscopy using its inherent fluorescence; (2) it is lysosomotropic enabling lysosomal targeting; and (3) as acridine is a P-glycoprotein (Pgp) substrate, it facilitates lysosomal targeting, resulting in the drug overcoming Pgp-mediated resistance.

View Article and Find Full Text PDF

P-glycoprotein (Pgp) is known for its dichotomous roles as both a safeguarding efflux transporter against xenobiotics and as a catalyst for multidrug resistance. Given the susceptibility of numerous therapeutic compounds to Pgp-mediated resistance, compliance with Food and Drug Administration (FDA) guidelines mandates an in-depth transport assay during drug development. This study introduces an innovative transport assay that aligns with these regulatory imperatives but also addresses limitations in the currently established techniques.

View Article and Find Full Text PDF